Medindia

X

Aethlon Medical To Present At ROTH Capital Partners 29th Annual Growth Stock Conference On March 14, 2017

Wednesday, March 8, 2017 General News J E 4
Advertisement

SAN DIEGO, March 8, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at the ROTH Capital Partners 29th Annual Growth Stock Conference in Dana Point, CA at 10:30 a.m. PT (1:30 p.m. ET) on Tuesday, March 14, 2017. 

The presentation will be made available to the public via live audio webcast which can be accessed by visiting the investor relations section of Aethlon Medical's corporate website at http://www.aethlonmedical.com. The webcast will be available for replay approximately one hour after the conclusion of the live event. 

About Aethlon Medical, Inc.

Aethlon Medical develops immunotherapeutic technologies to combat infectious disease and cancer.  To augment the body's natural immune defenses, the Aethlon Hemopurifier® reduces the presence of circulating viruses in infected individuals.  The technology provides a first-line candidate defense against viruses that are not addressed with proven drug therapies, including natural occurring pandemic threats and agents of bioterrorism.  The Hemopurifier® can also be deployed as a strategy to improve the benefit of approved antiviral drug regimens.  At present, the Hemopurifier® is being advanced in the United States under an FDA approved clinical study.  Aethlon Medical is also investigating the potential use of the Hemopurifier® to reduce the presence of tumor-derived exosomes, which contribute to immune-suppression and the spread of metastasis in cancer patients.  Aethlon Medical is also the majority owner of Exosome Sciences, Inc. (ESI), which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disorders, including Alzheimer's disease (AD) and Chronic Traumatic Encephalopathy (CTE).  ESI's TauSome™ biomarker is being clinically evaluated as the basis for a blood-based test to identify CTE in living individuals.  Additional information can be found online at www.AethlonMedical.com and www.ExosomeSciences.com.  You can also connect with us on Twitter, LinkedIn, Facebook and Google+.

Contacts:

Jim FrakesChief Financial OfficerAethlon Medical, Inc. 858-459-7800 extension 3300Jfrakes@aethlonmedical.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aethlon-medical-to-present-at-roth-capital-partners-29th-annual-growth-stock-conference-on-march-14-2017-300419676.html

SOURCE Aethlon Medical, Inc.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Wolf Administration Strengthening Mental Health an...
S
A mobile approach to diabetes management: Ascensia...